Emyria Enters Data Deal with ZLD to Support Autism Trial
Filed with ASX · · 3 pages · English
Highlights: ● Observational trial will collect efficacy and safety data from patients with Autism Spectrum Disorder (ASD) that have been prescribed one or more HOPE™ products ● Leverages Emyria’s real-world data expertise and national network of clinics – Emerald Clinics - to facilitate patient access ● Emyria data to inform product development and evaluation of a path to registration ● Partnershi
Story so far
Earlier from Emyria
- Webinar on Global Partnership with Sapphire Medical Clinics
- Emyria Signs Real-World Data Agreement with Zelira
- Preliminary Final Report and Full Year Statutory Accounts
- Emerald Clinics Successfully Raises $2.2m in Placement
- Record Appointments International Expansion and Name Change
Later from Emyria
- Emyria Partners with Thought Leaders in Psychedelic Therapy
- Emyria Launches Drug Development Program Based on RWE
- Emyria Sees Strong Interest in IBS Study
- Emyria to Benefit from Final TGA Ruling on CBD Medicines
- Emyria Pursuing Registration of EMD-003 in CY2021
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria